The Innovation Workshop will open for registration at 11:00 AM on 5th June 2014 with talks starting at 12:00 PM. The workshop will adjourn at approx. 4:30 PM on 6th June 2014.

Program Overview:

June 5th 2014

12:00 – 12:10 Welcome Speech
Christa Maar

German Network Against Colorectal Cancer and Felix Burda
Foundation, Munich
Otmar D. Wiestler
German Cancer Research Center, Heidelberg

12:10 – 12:40 Key Note Speech

Harald zur Hausen
German Cancer Research Center, Heidelberg
Key Note Speech: Links of Colorectal Cancer to Infections

Session I: Innovative Approaches in Colorectal Cancer Early Detection
Chair: Hermann Brenner

12:40 – 13:00 Frank Kolligs, Hospital Großhadern, University of Munich
Imaging of The Colon: State of The Art

13:00 – 13:20 John E. Blume, Applied Proteomics Inc., San Diego
Using Targeted Mass Spectrometry to Identify a Plasma-Based
Protein Marker Panel for Colorectal Cancer Risk Determination

13:20 – 13:40 Markus F. Neurath, University Hospital, Erlangen
A Pilot Study for Identification of Serum Markers for Colorectal Polyps

13:40 – 14:00 Hans Jørgen Nielsen, Hvidovre Hospital, University of Copenhagen
Development of a Screening Concept for CRC Based on Biological Markers in Blood

14:00 – 14:20 COFFEE BREAK

14:20 – 14:40 Friedrich-Wilhelm Tiller, Bavaria Health Center, Munich
Probing of Tandem-Mass-Spectrometry as a Non-Immunochemical Reference Method for Hb Quantification in Feces

14:40 – 15:00 Polly A. Newcomb, Fred Hutchinson Cancer Research Center, Seattle
New Colorectal Cancer Precursors: From Microscope to MicroRNA

15:00 – 15:20 Hermann Brenner, German Cancer Research Center, Heidelberg
Innovative Epidemiology for Colorectal Cancer Early Detection

15:20 – 15:40 COFFEE BREAK

Session II: Aspirin in Colon Cancer Prevention
Chair: Cornelia Ulrich & Jürgen Riemann

15:40 – 16:00 John A. Baron, Cancer Hospital, University of North Carolina
Aspirin and Vitamin D in Cancer Prevention: The Evidence Today

16:00 – 16:20 Nadir Arber, Tel Aviv Medical Center
Personal Aspirin Therapy

16:20 – 16:40 Gabriela G. Möslein, HELIOS St. Josefs Hospital, Bochum-Linden
The German Status of Moving Anti-Inflammatory Drugs Into The Clinic for High-Risk Individuals

16:40 – 17:00 Cornelia Ulrich, National Center for Tumor Diseases, Heidelberg
Pharmacogenetics of Aspirin and Anti-Inflammatory Agents:
Moving Towards Translation Through Personalized Prevention Strategies

17:00 – 17:20 COFFEE BREAK

Session III: Immunotherapy in Colorectal Cancer
Chair: Dirk Jäger

17:20 – 17:40 Niels Halama, National Center for Tumor Diseases, Heidelberg
The Immunological Landscape of Metastatic Colorectal Cancer: Cells, Cytokines and Treatment Decisions

17:40 – 18:00 Ugur Sahin, TRON Translational Oncology, University Mainz
Genomics Engineered Personalized Cancer Immunotherapy

18:00 – 18:20 Philipp Beckhove, German Cancer Research Center, Heidelberg
CRC Prognosis is Determined by in Situ Activity of Tumor Specific TIL

18:20 – 18:40 Hans-Georg Rammensee, University Hospital Tuebingen
Peptide-Based Immunotherapy of Cancer

18:40 – 19:00 Magnus von Knebel-Doeberitz
, University Hospital, Heidelberg
The Immune Biology of DNA Mismatch Repair Deficient Tumor Cells: Towards a Vaccine for Hereditary Colon Cancer


June 6th 2014

Session IV: Genomics, Epigenetics and Risk Stratification of Colorectal Cancer
Chair: Hanno Glimm

09:00 – 09:20 Jane C. Figueiredo, University of Southern California
Genome-Wide Studies of Gene-Dietary Interactions and Colorectal Cancer Risk

09:20 – 09:40 Davina Gale, Cancer Research UK Cambridge Institute, University of Cambridge
Non-Invasive Analysis of the Cancer Genome Using Circulating Tumor DNA

09:40 – 10:00 Matthias Kloor, University Hospital Heidelberg
Colorectal Cancer Syndromes – Novel Insights

10:00 – 10:20 Joachim P. Spatz, Max Planck Institute for Intelligent Systems, Stuttgart and
University of Heidelberg
Marker-Free Phenotyping of Tumor Cells by Fractal Analysis of Optical Microscopy Image

10:20 – 10:40 COFFEE BREAK

Session V: Colon Microbiome
Chair: Dirk Haller

10:40 – 11:00 Meredith A. J. Hullar, Fred Hutchinson Cancer Research Center, Seattle
The Colon Microbiome Associated with Human Health

11:00 – 11:20 Mathias Chamaillard, Institut Pasteur de Lille
Remote Control of Intestinal Inflammation and Tumorigenesis by the Intestinal Microbiota

11:20 – 11:40 Peer Bork, European Molecular Biology Laboratory, Heidelberg
Diagnostic Potential of Faecal Microbiota Associated with Colorectal Cancer

11:40 – 12:00 Stephen J. D. O’Keefe, Departement of Medicine, University of Pittsburgh
Diet, the Microbiome and Cancer Risk: Switching Diets between High Colon Cancer Risk Americans and Low Risk Africans

12:00 – 12:20 Jiyoung Ahn, New York University School of Medicine
Human Gut Microbiome, Fiber Intake, and Colorectal Cancer Risk

12:20 – 12:40 Christian Jobin
, Departement of Medicine, University of Florida, Gainesville
Inflammation is Essential for Microbial-Induced Carcinogenic Properties in the Intestine

12:40 – 13:30 LUNCH BREAK

Session VI: Oncology Pipelines
Chair: Georg Ralle & Christof von Kalle

Presentation of New Developments of Pharmaceutical Industry:

13:30 - 13:50 Uwe Phillip Strauss, Bayer Vital GmbH, Leverkusen

13:50 - 14:10 Florin Sirzen, F. Hofmann-La Roche, Basel

14:10 - 14:30 N.N., Merck Serono GmbH, Darmstadt

14:30 - 14:50 Stephan Brock, Molecular Health GmbH, Heidelberg

14:50 - 15:10 Bernd Müller, MSD SHARP & DOHME GMBH, Haar

15:10 – 15:30 LUNCH BREAK

Session VII: Panel Discussion
15:30 – 17:00

Jörg Rüdiger Siewert, Medical Director & President of the University Hospital Executive Board of Directors of the University Hospital of Freiburg

Participants of the Panel Discussion:

  • Friedrich von Bohlen, dievini Hopp BioTech holding GmbH & Co. KG, Walldorf
  • Werner Eberhardt, SAP, Walldorf
  • Michael Hallek, Head of Hospital I for Internal Medicine, University of Cologne
  • Otmar D. Wiestler, Chairman & Scientific Director of German Cancer Research Center, Heidelberg

to top
powered by webEdition CMS